銀禧科技(300221.SZ):銀禧集團終止大宗交易減持計劃 擬通過集中競價繼續減持不超1%股份
格隆匯2月6日丨銀禧科技(300221.SZ)公佈,公司近日收到銀禧集團出具的《關於銀禧集團終止大宗交易減持計劃及擬進行集中競價減持的告知函》,銀禧集團決定終止2019年7月23日發佈的大宗交易減持計劃,並於公司公告發布之日起15個交易日後3個月內,以集中競價交易方式減持公司股份不超過約449.94萬股(不超過佔扣除回購專户後公司的總股本1%)。
銀禧集團於近日給公司出具了告知函,決定終止2019年7月23日的大宗交易減持計劃。綜上所述,銀禧集團已完成其2019年7月23日出具的減持計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.